A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adult Subjects With Friedreich Ataxia
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2019
Price : $35 *
At a glance
- Drugs TAK 831 (Primary)
- Indications Friedreich's ataxia
- Focus Therapeutic Use
- Sponsors Takeda
- 07 Jan 2019 Status changed from active, no longer recruiting to completed.
- 28 Sep 2018 Planned End Date changed from 27 Feb 2019 to 4 Jan 2019.
- 28 Sep 2018 Planned primary completion date changed from 27 Feb 2019 to 4 Jan 2019.